Clinical trials: TACE, completed
Hepatocellular Carcinoma
Transarterial Ethanol Ablation (TEA) Versus Transcatheter Arterial Chemoembolisation (TACE) for Hepatocellular Carcinoma
The current randomized controlled trial comparing LEM and TACE aims to evaluate the safety and efficacy of LEM as compared to TACE for treating patients with unresectable HCC.
- Trial name
- NCT00467974
- Testing
- TEA with LEM, TACE
- Where
- 3 sites in Hong Kong
- Volunteers
- 98 people
- Sponsor
- Chinese University of Hong Kong
Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma
CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
The purpose of this study is to determine the safety and efficacy of immunotherapy durvalumab and tremelimumab combined with DEB-TACE in patients with Hepatocellular Carcinoma.
- Trial name
- NCT03638141
- Testing
- Durvalumab, Tremelimumab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatocellular Carcinoma
Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection
Hepatectomy is still the treatment of choice for hepatocellular carcinoma. Part of the patients may present portal vein tumor thrombus (PVTT) after resection.
- Trial name
- NCT00825669
- Testing
- TACE, Laser ablation
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma Non-resectable
TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
This study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab in patients with unresectable intermediate or advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT04592029
- Testing
- TACE combined with sintilimab and bevacizumab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Liver Cancer, Liver Neoplasm
Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization
Background: Treatment for liver cancer can include surgery, transplant, and chemotherapy. It can also include other minimally invasive tumor treatments such as transarterial chemoembolization (TACE).
- Conditions
- Liver Cancer, Liver Neoplasm, Hepatocellular Carcinoma, HCC
- Trial name
- NCT02471313
- Testing
- [18F] FMISO
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatocellular Carcinoma Non-resectable
TACE Combined With Sorafenib and Tislelizumab for Advanced HCC
This study will evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with sorafenib and tislelizumab in patients with advanced hepatocellullar carcinoma (HCC).
- Trial name
- NCT04599777
- Testing
- TACE combined with sorafenib and tislelizumab
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Liver Transplantation
Tumor Feeding Vessels Deprivation Combined With Tyrosine Kinase Inhibitor in Liver Transplantation
To investigate the value of tumor feeding vessels deprivation combined with tyrosine kinase inhibitor in liver transplantation. Patients are enrolled into two groups according to the downstaging therapy they undergo before…
- Trial name
- NCT05448339
- Testing
- PVHA or TACE
- Where
- China
- Volunteers
- 197 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Hepatocellular Carcinoma
TACE Combined With RFA/MV Treatment in Hepatocellular Carcinoma Beyond Milan Criterial
This study was designed to evaluate the effectiveness of radiofrequency /microwave ablation in patients with hepatocellular carcinoma beyond Milan Criteria.
- Trial name
- TACE+RFA (NCT03636620)
- Testing
- Transcatheter arterial chemoembolization, radiofrequency ablation/microwave ablation
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Fudan University
Carcinoma. Hepatocellular
Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis
The presence of portal vein tumor thrombosis (PVTT)in patients with HCC is one of the most significant prognostic factors for poor prognosis, without treatment, their survival is less than 3 months.
- Trial name
- NCT01911000
- Testing
- RT and hyperthermia after TACE
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- Samsung Medical Center
Colorectal Carcinoma, Neoplasm Metastasis
CIRSE Registry for LifePearl Microspheres
The application of transarterial chemoembolisation (TACE) using LifePearl Microspheres loaded with Irinotecan in liver-only or liver-dominant metastatic disease in patients with colorectal adenocarcinoma will be observed.
- Trial name
- CIREL (NCT03086096)
- Testing
- LifePearl Microspheres loaded with Irinotecan
- Where
- Austria
- Volunteers
- 152 people
- Sponsor
- Cardiovascular and Interventional Radiological Society of Europe
Hepatic Tumor
Impact of New Interventional Imaging Modality Use on Patient Radiation Exposure in Transarterial Chemoembolization
Transarterial chemoembolization (TACE) is the most performed endovascular interventional radiology (IR) procedure. TACE procedures are performed in an IR suite, most of which are equipped with floor-based flat-panel robotic C-arm…
- Trial name
- NCT03698643
- Where
- France
- Volunteers
- 145 people
- Sponsor
- University Hospital, Montpellier
Hepatectomy, Hepatocellular Carcinoma
Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)
The standard treatment choice for advanced hepatocellular carcinoma (HCC) is sorafenib, and its efficacy is limited. More active treatments were performed in patients with advanced HCC in China, which include radical hepatectomy…
- Conditions
- Hepatectomy, Hepatocellular Carcinoma, Sorafenib
- Trial name
- 2011PTAHCC (NCT01409499)
- Testing
- hepatic resection, transcatheter hepatic arterial chemoembolization, sorafenib
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Esophagogastric Varices
Efficacy of TACE With Endoscopic Therapy for Unresectable Hepatocellular Carcinoma
The study is aimed to explore the efficacy of transarterial chemoembolization (TACE) combined with endoscopic therapy for unresectable hepatocellular carcinoma (HCC) complicated with esophagogastric varices (EGV) and seek out…
- Trial name
- NCT05017922
- Testing
- transarterial chemoembolization combined with endoscopic therapy
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Qilu Hospital of Shandong University
Healthy Volunteers
Recruiting Blood Donor With Allogeneic Natural Killer Cell
This study on manufacture of MG4101 (allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) after Transarterial Chemoembolization(TACE) will be harvested WBC(white blood cell) and plasma from healthy donors, or…
- Trial name
- NCT02716571
- Testing
- Leukapheresis or Plasmapheresis
- Where
- South Korea
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma (HCC)
TACE for HCC by TANDEM and Idarubicin
DcBeads and lipiodol-transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using doxorubicin result in about 50% objective response rate at 6 months (Precision V study, Lammer et al.
- Trial name
- TANDEM-IDA (NCT03349957)
- Testing
- Transarterial chemoembolization using TANDEM and idarubicin
- Where
- France
- Volunteers
- 98 people
- Sponsor
- University Hospital, Montpellier
Hepatic Carcinoma
Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
Clinically significant portal hypertension limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis.
- Trial name
- NCT06245798
- Testing
- transarterial chemoembolisation
- Where
- 2 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Tang-Du Hospital
Hepatocellular Carcinoma
cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria
This study will evaluate the efficacy and safety of Sintilimab plus Transcatheter arterial chemoembolization (TACE) in participants with Intermediate-stage unresectable hepatocellular carcinoma with Beyond Up-to-seven Criteria.
- Trial name
- NCT04842565
- Testing
- Sintilimab, TACE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Hepatocellular Cancer
A Pilot Study of "OncozeneTM" Microspheres for Intra-arterial Delivery of Doxorubicin
This is a pilot study of Onconzene Microspheres for intra-arterial delivery of doxorubicin for the treatement of patients with unresectable hepatocellular cancer.
- Trial name
- NCT02141906
- Testing
- Oncozene-DEB-TACE
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Texas Southwestern Medical Center
Hepatocellular Carcinoma, TACE
Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1
In order to provide a new option for clinical anti-angiogenesis therapy in hepatoma, a randomized controlled study is planed to confirm the effect of Rg3 in combination with TACE on angiogenesis and tumor treatment in advanced…
- Conditions
- Hepatocellular Carcinoma, TACE, Notch1, Rg3
- Trial name
- NCT02724358
- Testing
- TACE, Rg3, TACE + Rg3
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Carcinoma, Hepatocellular, Liver Neoplasms
A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)
The purpose of the study is to assess the survival of patients treated with Litx™ versus standard of care therapies in the treatment of unresectable hepatocellular carcinoma (HCC), and to demonstrate the safety of Litx™ therapy.
- Trial name
- NCT00355355
- Testing
- Talaporfin sodium, Interstitial Light Emitting Diodes, Percutaneous placement of device in the liver
- Where
- 34 sites in Croatia, Hong Kong and 9 more
- Volunteers
- 208 people
- Sponsor
- Light Sciences Oncology